T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action
Homer Adams,Frederik Stevenaert,Jakub Krejcik,Jakub Krejcik,Koen Van der Borght,Tineke Casneuf,Tina Smets,Jaime Bald,Yann Abraham,Hugo Ceulemans,Greet Vanhoof,Tahamtan Ahmadi,Saad Z. Usmani,Torben Plesner,Sagar Lonial,Berris van Kessel-Welmers,Henk M. Lokhorst,Tuna Mutis,Niels W.C.J. van de Donk,A. Kate Sasser +19 more
TL;DR: Next-generation mass cytometry and high-dimensional CyTOF analyses confirmed previous findings including higher CD38 expression on plasma cells compared with other immune populations of natural killer (NK), monocytes, B and T cells, and depletion of both plasma cells and NK cells upon DARA treatment.
Journal ArticleDOI
Sézary syndrome: phenotypic and functional characterization of the neoplastic cells
Elisabeth Ralfkiaer,Gunhild Lange Wantzin,Joergen K. Larsen,Vagn Andersen,Christian H. Geisler,Torben Plesner,Kristian Thomsen +6 more
TL;DR: Data provide conclusive evidence that Sézary syndrome is heterogeneous with respect to the immunological characteristics of the neoplastic cells.
Journal ArticleDOI
Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.
Aurore Perrot,Thierry Facon,Torben Plesner,Saad Z. Usmani,Shaji Kumar,Nizar J. Bahlis,Karthik Ramasamy,Murielle Roussel,Carla Araujo,Arnaud Jaccard,Michel Delforge,Caroline McKay,Katharine S. Gries,Jeremiah J. Trudeau,Cyrille Hulin,Katja Weisel +15 more
TL;DR: MAIA, an ongoing phase 3 trial of transplant-ineligible patients with NDMM, demonstrated significant improvement in progression-free survival with D-Rd vs Rd alone.
Journal ArticleDOI
Failure to synthesize the human T-cell CD3-zeta chain and its consequence for the T-cell receptor-CD3 complex expression.
TL;DR: The data indicate that the CD3‐ζ determines the normal intracellular fate of the TcR‐CD3 complex, and that theCD3‐ ζ is necessary for the intrACEllular transport and expression at the cell surface of the R‐cell antigen receptor complex.